OBJECTIVE Although initially effective, sulfonylureas are associated with poor glycemic
durability, weight gain, and hypoglycemia. Dapagliflozin, a selective inhibitor of sodium …

OBJECTIVE Insulin adjustments to maintain glycemic control in individuals with type 1
diabetes often lead to wide glucose fluctuations, hypoglycemia, and increased body weight …

Background Management of type 2 diabetes with metformin often does not provide
adequate glycemic control, thereby necessitating add-on treatment. In a 24-week clinical …

OBJECTIVE To evaluate the efficacy and safety of dapagliflozin in patients with type 2
diabetes inadequately controlled with metformin and sulfonylurea. RESEARCH DESIGN …

Aims To assess the long‐term efficacy and tolerability of dapagliflozin versus glipizide as
add‐on to metformin in patients with inadequately controlled type 2 diabetes. Methods The …

Aims To assess the long‐term glycaemic durability, safety and tolerability of dapagliflozin
versus glipizide as add‐on therapies in patients with type 2 diabetes inadequately controlled …

OBJECTIVE This 24-week, double-blinded, phase 3 clinical trial (DEPICT-2; ClinicalTrials.
gov, NCT02460978) evaluated efficacy and safety of dapagliflozin as adjunct therapy to …

Aims Many patients with type 2 diabetes are suboptimally managed with currently available
therapies. Dapagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, has shown efficacy in …

Introduction Maintenance of drug efficacy and safety over the long term is important to
investigate for progressive conditions like type 2 diabetes mellitus (T2DM). This study aimed …

Background: Dapagliflozin, a selective inhibitor of sodium–glucose cotransporter 2, may
improve glycemic control with a lower dose of insulin and attenuate the associated weight …